Linda Avey is a founding general partner at Humain Ventures, an Austin, TX-based venture capital firm investing at the intersection of AI and the bioeconomy. Linda has been at the forefront of the digital health movement. As the visionary founder of 23andMe, the company assembled a research repository of genetic and phenotypic data to study human disease. The company now houses the largest research database of recontactable participants. As co-founder of Precisely, Inc., she focused on methods to automate clinical protocols to improve outcomes and lower costs. Linda is a member of the Board of Fellows at Stanford Medical Center and is an advisor to Colossal Biosciences. She previously served on the advisory board of Verily, Alphabet’s life science subsidiary.
Programming descriptions are generated by participants and do not necessarily reflect the opinions of SXSW.